General
Preferred name
ANASTROZOLE
Synonyms
ZD1033 ()
Arimidex ()
ICI D1033 ()
Arimidex (Zeneca) ()
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile ()
ANAS ()
1,3-Benzenediacetonitrile,.alpha.,alpha.,alpha.',.alpha.'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- ()
Anastrozole (ZD-1033) ()
Arimidex,ZD-1033 ()
NSC-759855 ()
Nastrosa ()
ZD-1033 ()
Rvg-106400 ()
Anastrozol ()
ICI-D1033 ()
NSC-719344 ()
Anastrozole-d12 ()
P&D ID
PD003143
CAS
120511-73-1
120512-32-5
Tags
available
drug
Approved by
FDA
First approval
1995
Drug indication
Breast cancer
Antineoplastic
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Anastrozole decreases the amount of estrogens that the body makes by inhibiting the enzyme aromatase, which is responsible for converting androgens to estrogens in females.
(GtoPdb)
DESCRIPTION
Selective FAK inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Potent aromatase (CYP19) inhibitor
(Tocriscreen Plus)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
36
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
48
Molecular Weight
293.16
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
2.93
TPSA
78.29
Fraction CSP3
0.41
Chiral centers
0.0
Largest ring
6.0
QED
0.87
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
MOA
Aromatase inhibitor
Inhibitor
Aromatase Inhibitors
Target
Cytochrome P450 19A1
Aromatase
CYP19A1
Pathway
Endocrinology/Hormones
Metabolic Enzyme/Protease
Primary Target
Cytochrome P450
Member status
virtual
Indication
breast cancer
Therapeutic Class
Anticancer Agents
Source data
